We serve Chemical Name:2-Nitrophenylacetonitrile CAS:610-66-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-Nitrophenylacetonitrile
CAS.NO:610-66-2
Synonyms:MFCD00007183;2-(2-nitrophenyl)acetonitrile;EINECS 210-231-0
Molecular Formula:C8H6N2O2
Molecular Weight:162.14500
HS Code:2926909090
Physical and Chemical Properties:
Melting point:82-85 °C(lit.)
Boiling point:178°C
Density:1.272 g/cm3
Index of Refraction:1.577
PSA:69.61000
Exact Mass:162.04300
LogP:2.18408
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:3439
Packing Group:III
Contact us for information like MFCD00007183 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,EINECS 210-231-0 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-(2-nitrophenyl)acetonitrile Use and application,2-(2-nitrophenyl)acetonitrile technical grade,usp/ep/jp grade.
Related News: Different cell types can be affected, although the most common finding in MDS is a shortage of red blood cells (anaemia). Patients with higher-risk MDS may progress to the development of acute leukaemia. 2-Nitrophenylacetonitrile manufacturer Microarrays of over 5,500 plasma membrane and secreted protein targets are expressed in human cells. 2-Nitrophenylacetonitrile supplier Different cell types can be affected, although the most common finding in MDS is a shortage of red blood cells (anaemia). Patients with higher-risk MDS may progress to the development of acute leukaemia. 2-Nitrophenylacetonitrile vendor ICIG has agreed to offer employment to the unit��s approximately 120 employees upon closing, and plans to maintain operations at its primary location, a manufacturing facility in Liestal, Switzerland. 2-Nitrophenylacetonitrile factory Analysts at Jefferies, meanwhile, said the FDA accelerated approval for Aduhelm, which was based on a surrogate endpoint of amyloid beta plaque reduction (and not clinical benefit) “has implications for ongoing AD studies,” most notably, it reckons, for Roche’s phase 3 GRADUATE test for its anti-amyloid-beta candidate gantenerumab, “as a much lower hurdle than demonstrating clear cognitive benefit” has now become precedent. Jefferies, still cautious, said it remains “unclear what stance FDA may take for the field if GRADUATE fails on cognition despite significant Abeta reductions,” but says it’s probably not going to revive Roche-AC Immune’s anti-amyloid-beta candidate crenezumab, which saw its late-stage CREAD trials discontinued for futility but which is currently in an Alzheimer’s prevention study.
